Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
151
resultados
Última actualización
03/05/2025 [06:59:00]
Resumen de: WO2025090855A1
Provided are a method, system, and computer-readable medium for personalizing titration measurement for basal insulin dosing. The personalization can be achieved using spare self-monitoring blood glucose (SMBG) and/or dense continuous glucose monitoring (CGM) data to predict a fasting blood glucose (FBG) envelope accounting for online estimation of titration noise representative of variability in daily fasting measurement. As a result, basal insulin dosing directed to causing the FBG envelope to be maintained for an optimal glycemic range can then be obtained.
Resumen de: WO2025090951A1
An artificially intelligent, voice-based method for prescribing, managing and administering at least one medication for management of type 2 diabetes to a patient. Aspects of the present disclosure provide for a system and method for configuring one or more clinical algorithms according to one or more clinical protocols to configure a conversational Al model. The conversational Al model is configured to drive a conversational Al agent configured to facilitate a plurality of multi-turn conversational interactions between a patient user and the conversational agent to enable automated initiation and titration of one or more diabetes medications for the patient.
Resumen de: AU2023372542A1
Embodiments can relate to a system for automatically detecting sensor compression in continuous glucose monitoring including at least one sensor and at least one processor in communication with the at least one sensor, the at least one processor executing at least two machine learning models, wherein the at least one processor is programmed or configured to cause the processor to receive, from the at least one sensor, measurement data including at least one time series of blood glucose (BG) measurements measured by the at least one sensor, determine that the at least one time series of BG measurements is a candidate series including a compression artifact using a first machine learning model, and generate, using a second machine learning model, a signal output indicating that the at least one time series of BG measurements was obtained while the at least one sensor was subject to compression.
Resumen de: AU2023372535A1
Embodiments can relate to systems and methods for automatically detecting sensor compression in continuous glucose monitoring in real time. A system may include at least one sensor and at least one processor in communication with the at least one sensor. The at least one processor is programmed or configured to cause the processor to retrieve first measurement data including at least one time series of blood glucose (BG) measurements, the at least one time series being measured by the at least one sensor while not subject to compression; receive, from the at least one sensor, second measurement data including at least one BG measurement; determine a clearance value between BG measurements based on the first measurement data and the second measurement data; and generate a signal output indicating that the at least one sensor is subject to compression based on the clearance value between BG measurements exceeding a predefined threshold.
Resumen de: US2025140393A1
Systems and methods for glucose device batch analyses. An example method includes obtaining analysis datasets reflecting manufacturing information associated with medical devices included in a device batch, the manufacturing data measuring information associated with individual manufacturing steps, and with the analysis datasets being formatted for input into a machine learning model, and with unique identifying information associated with the medical devices being used to aggregate analysis datasets specific to the medical devices. The analysis datasets are provided to the machine learning model, with the machine learning model being trained to output performance information for individual medical devices indicating whether they are in releasable condition. The machine learning model was trained based on ground truth associated with manufactured devices, and the ground truth was derived based on test information associated with the manufactured devices. An interactive user interface is generated which presents summary information associated with the performance information.
Resumen de: US2025134381A1
A biometric wearable device (e.g. finger ring or smart watch) has optical sensors to measure body oxygenation level, hydration level, glucose level, heart rate, heart rate variability, and/or blood pressure. Light from light emitters is transmitted through body tissue and changes in the light are analyzed. In an example, the device can include body-facing protrusions where the light emitters and/or the light receivers are located.
Resumen de: US2025134417A1
A processor-implemented method includes receiving sensor measurement data from a glucose sensor; selecting, based on the sensor measurement data, a first regional sensor glucose (SG) model from a first plurality of regional SG models for respective regions of a first plurality of regions of an input parameter space associated with the sensor measurement data, and a second regional SG model from a second plurality of regional SG models for respective regions of a second plurality of regions of the input parameter space; estimating a first SG value and a second SG value using the first regional SG model and the second regional SG model, respectively; and determining a predicted SG value based on a combination of the first SG value and the second SG value. The input parameter space is partitioned into the first plurality of regions and the second plurality of regions using different partition schemes.
Resumen de: US2025134419A1
Provided relates to a continuous blood glucose measurement device which is produced with an assembled body attachment unit inside an applicator so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body by simply activating the applicator, and which is provided with a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use, without additional work of connecting a separate transmitter, and easier maintenance; and is activated by the user after the body attachment unit is attached to the body so as to enable the operation start time to be adjusted to an appropriate time according to user's needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.
Resumen de: US2025134416A1
Techniques disclosed herein relate to glucose level measurement and/or management. In some embodiments, the techniques involve obtaining in vivo characteristics of a glucose sensor predicted using fabrication process measurement data associated with the glucose sensor, the in vivo characteristics including an in vivo sensitivity, an in vivo intercept, or a combination thereof; receiving sensor measurement data measured by the glucose sensor, the sensor measurement data including sensor current (Isig), counter voltage (Vcntr), electrochemical impedance spectroscopy (EIS) data, an age of the glucose sensor, or a combination thereof; and estimating a sensor glucose (SG) value using an SG model, wherein input parameters of the SG model include the in vivo characteristics of the glucose sensor and the sensor measurement data, and the SG value is an output of the SG model.
Resumen de: WO2025086630A1
Disclosed are a postprandial insulin infusion system and method based on recognizable features of a diabetic patient. A food image is acquired by an imaging module, and the food image is analyzed by a food image recognition model to obtain food data. According to the recognizable features of the patient, a narrow-sense insulin algorithm adapted to the recognizable features of the patient is retrieved from a narrow-sense insulin algorithm cluster and used for calculating an insulin infusion amount during the meal. Compared with a preset insulin algorithm, the narrow-sense insulin algorithm is more adapted to the physiological characteristics and living habits of the patient, and the calculated postprandial insulin infusion amount is more accurate, which is conducive to the treatment of diabetes in the patient.
Resumen de: WO2025086631A1
Disclosed in the present invention are a closed-loop infusion system and method based on food image recognition. A food image is acquired by an imaging module, and the food image is analyzed by a food image recognition model to obtain food data. An insulin algorithm determines a postprandial insulin infusion amount for a patient on the basis of the food data and simulates postprandial blood glucose for the patient. While infusing insulin, an artificial pancreas collects real-time blood glucose data. The real-time blood glucose data are compared with the simulated blood glucose data, and the comparison result is used for correcting parameters of the insulin algorithm, making the insulin algorithm more suitable for the patient. The present invention improves the accuracy and adaptability of the insulin algorithm, which is conducive to the treatment of diabetes in the patient.
Resumen de: US2025134463A1
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Resumen de: EP4545004A2
Systems and methods for providing sensitive and specific alarms indicative of glycemic condition are provided herein. In an embodiment, a method of processing sensor data by a continuous analyte sensor includes: evaluating sensor data using a first function to determine whether a real time glucose value meets a first threshold; evaluating sensor data using a second function to determine whether a predicted glucose value meets a second threshold; activating a hypoglycemic indicator if either the first threshold is met or if the second threshold is predicted to be met; and providing an output based on the activated hypoglycemic indicator.
Resumen de: EP4545005A2
The present disclosure relates to a diabetes management system and methods related to the same. The system includes a pump device and a controller. The controller receives blood glucose data, determines basal insulin dosages based on stored baseline basal rates, controls insulin dispensation based on the determined basal insulin dosages, modifies a target blood glucose levels, receives a temporary override indicating a user preference to reduce the likelihood of a hypoglycemic or hyperglycemic event, determines a temporary target blood glucose level accordingly, and controls dispensation according to the temporary target blood glucose level. The controller can also calculate a probability that a blood glucose level crosses a threshold, determine a target blood glucose level based on a fear of hypoglycemia index and the calculated probability, determine insulin delivery information according to the target blood glucose level, and control dispensation accordingly.
Resumen de: EP4545001A1
A diabetes risk detection method, an electronic device, and a system are disclosed and are applied to the field of terminal technologies, to resolve a problem in the conventional technology that an obtained diabetes risk detection result is inaccurate when time for collecting a PPG signal is short. The method includes: obtaining first data and second data, where the first data includes a photoplethysmography PPG signal obtained via a PPG sensor, and the second data includes one or more of the following: diet data, exercise data, physical symptom data, drug use data, sleep data, and emotion data; determining a diabetes risk detection result based on the first data and the second data; and finally outputting the diabetes risk detection result to prompt a user with a health status.
Resumen de: EP4546365A2
Systems and methods for automatically delivering medication to a user. A sensor coupled to a user can collect information regarding the user. A controller can use the collected information to determine an amount of medication to provide the user. The controller can instruct a drug delivery device to dispense the medication to the user. The drug delivery device can be a wearable insulin pump that is directly coupled to the user. The controller can be part of or implemented in a cellphone. A user can be required to provide a confirmation input to allow a determined amount of insulin to be provided to the user based on detected glucose levels of the user. The sensor, controller, and drug delivery device can communicate wirelessly.
Resumen de: EP4546359A2
A medicament delivery system, process and techniques are provided. The medicament delivery system may include a wearable medicament delivery device, a memory storing programming instructions, and a processor. The processor may be operable to execute the programming instructions, which cause the processor to receive an available medicament delivery history of a user, and determine whether the available medicament delivery history spans an extent of time greater than a first glucose history duration. The processor, in response to a determination that the extent of time spanned by the available medicament delivery history is greater than the first glucose history duration, determines an average daily medicament delivered. The processor calculates a trust value of the available medicament delivery history, and utilizes the trust value to determine a total daily medicament value of the user.
Resumen de: EP4545007A1
Implantable device for measuring the glucose concentration of a body fluid when implanted, the device comprising a glucose measurement unit, the glucose measurement unit comprising a light source configured to emit light towards a light transmissive part of a housing of the device, the device further comprising an optical sensor configured to detect light returned through the transmissive part from the light source, and output an electrical signal based on the detected light, and a wireless communication module configured to wirelessly communicate with an external wireless communication device, wherein the wireless communication module is configured to wirelessly transmit a signal based on the electrical signal to the external wireless communication device.
Resumen de: EP4545003A2
The present invention relates to a body attachment unit for continuous blood glucose monitoring, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and activation can occur in a stabilized state, and thereby allowing more accurate blood glucose monitoring.
Resumen de: EP4545002A1
A processor-implemented method includes receiving sensor measurement data from a glucose sensor; selecting, based on the sensor measurement data, a first regional sensor glucose (SG) model from a first plurality of regional SG models for respective regions of a first plurality of regions of an input parameter space associated with the sensor measurement data, and a second regional SG model from a second plurality of regional SG models for respective regions of a second plurality of regions of the input parameter space; estimating a first SG value and a second SG value using the first regional SG model and the second regional SG model, respectively; and determining a predicted SG value based on a combination of the first SG value and the second SG value. The input parameter space is partitioned into the first plurality of regions and the second plurality of regions using different partition schemes.
Resumen de: WO2025085172A1
A dialysis-ultrasound system is described that includes an ultrasound therapy device integrated with a catheter to incorporate ultrasound therapy into a dialysis system. The ultrasound device may be or may include a high-intensity focused ultrasound (HIFU) device or peripheral focused ultrasound stimulation (pFUS) device. The ultrasound therapy may target the liver, for example, to treat diabetes. In one example, a system includes a catheter configured to be arranged within the peritoneal cavity of a patient for peritoneal dialysis (PD), and an ultrasound device configured to emit ultrasound waves. The ultrasound device is integrated with the catheter and is arranged on the catheter to be implanted within the peritoneal cavity of the patient to provide ultrasound therapy to a target region of the patient. Other embodiments are described.
Resumen de: US2023011856A1
An arrangement for operating a biosensor emitting radiation includes an excitation light source, which generates at least one excitation radiation for the biosensor; a coupling fiber, at the entry surface of which the excitation radiation is coupled in; an optical Y-coupler, including an excitation arm, which is connected to the exit surface of the coupling fiber, a detector arm, which is connected to an optical detector, and a sensor foot, which can be connected to the biosensor. The excitation arm has a conical shape. The radiation axis of the excitation arm includes an angle in the range of 5° to 70° with the main radiation axis of the detector arm. The diameter of the excitation arm at the connecting point to the detector arm is less than two thirds the diameter of the detector arm. An arrangement for determining the glucose content blood is also provided.
Resumen de: AU2023377269A1
A method, system, and computer-readable medium are provided for an Automated Insulin Delivery (AID) system in which Model Predictive Control (MPC) thereof implements weighting of glucose target error relative to corresponding predicted blood glucose (BG) levels according to insulin on board (IOB). Accordingly, basal insulin infusion and available additional bolusing each in connection with glycemic disturbances such as unannounced meals can be proximally administered to maintain time in range (TIR) without incurring insulin stacking.
Resumen de: US2025127429A1
A glucose detection or monitoring system that includes a VCSEL laser with one or more active regions having quantum wells and barrier. The active regions are surrounded by one or more p-n junctions. The one or more active regions can include a selected shape structure, and one or more tunnel junctions (TJ). One or more apertures are provided with the selected shape structure, one or more buried tunnel junctions (BTJ) or oxide confine apertured, additional TJ's, planar structures and or additional BTJ's created during a regrowth process that is independent of a first growth process with a VCSEL output determined in response to a monitoring application of the VCSEL, the VCSEL having an HCG grating and a bottom DBR. A housing of a wearable device interior houses the VCSEL laser.
Nº publicación: US2025127433A1 24/04/2025
Solicitante:
I SENS INC [KR]
I-SENS, INC
Resumen de: US2025127433A1
A blood glucose measurement device according to an embodiment of the present invention comprises: a measurement unit that is partially inserted into the body of a subject and generates a blood glucose measurement signal by measuring a blood glucose concentration of the subject; a control unit that generates blood glucose measurement data by converting the blood glucose measurement signal into digital data; and a storage unit that stores the blood glucose measurement data, wherein the control unit stores the preset first verification data in the storage unit, and stores the blood glucose measurement data in the storage unit continuously to the first verification data.
BOPI
Sede Electrónica
